Thomas McGauley bought $58k of TENX
Interim CFO at TENAX THERAPEUTICS, INC.. 8,000 shares at an average of $7.27, traded Nov 17, 2025, filed Nov 19, 2025.
Score components
- +22RoleCFO
- +7Trade size$58k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNear the top of the 52-week range
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +79.0%, 3m +70.8%, 6m +63.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001550701-25-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | POpen-market purchase Common Stock | +2,000 | $7.34 | $15k | 2,000 | Nov 19, 2025 |
| Nov 17, 2025 | POpen-market purchase Common Stockindirect: By Child | +1,000 | $7.35 | $7,350 | 1,000 | Nov 19, 2025 |
| Nov 17, 2025 | POpen-market purchase Common Stockindirect: By Spouse | +5,000 | $7.23 | $36k | 5,000 | Nov 19, 2025 |
Related signals
Other insiders at TENAX THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | TENAX THERAPEUTICS, INC. | Declan Doogan director | $102k 53,000 shares | +2331% | |
| 50Moderate | TENAX THERAPEUTICS, INC. | Christopher Thomas Giordano CEO | $20k 10,850 shares | +96% | |
| 47Moderate | TENAX THERAPEUTICS, INC. | Thomas R Staab II Chief Financial Officer | $11k 5,675 shares | +57% | |
| 63Notable | TENAX THERAPEUTICS, INC. | ADAR1 Capital Management, LLC owner | $1.6M 900,000 shares | +16% | |
| 63Notable | TENAX THERAPEUTICS, INC. | ADAR1 Capital Management, LLC owner | $1.4M 770,333 shares | +16% | |
| 46Moderate | TENXbuy TENAX THERAPEUTICS, INC. | ADAR1 Capital Management, LLC owner | $1.8M 1,025,867 shares | +27% | |
| 37Weak | TENXbuy TENAX THERAPEUTICS, INC. | Stuart Rich Chief Medical Officer | $51k 5,000 shares | +200% | |
| 39Weak | TENAX THERAPEUTICS, INC. | Stuart Rich Chief Medical Officer | $46k 5,000 shares | +1880% | |
| 48Moderate | TENAX THERAPEUTICS, INC. | Christopher Thomas Giordano CEO | $20k 2,605 shares | - | |
| 38Weak | TENAX THERAPEUTICS, INC. | June Sherie Almenoff director | $15k 1,993 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.